Treatment approaches to irritable bowel syndrome.
Sood
Manu R
MR
Division of Pediatric Gastroenterology and Nutrition, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, USA. Msood@mcw.edu
D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001521:Behavior Therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D015928:Cognitive Behavioral Therapy; D004043:Dietary Fiber / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000628:therapy*; D008139:Loperamide / Q000627:therapeutic use; D000068238:Lubiprostone; D008550:Melatonin / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010372:Pediatrics / Q000379:methods; D010819:Physician's Role; D011320:Primary Health Care / Q000379:methods; D019936:Probiotics / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000929:Antidepressive Agents, Tricyclic; D004043:Dietary Fiber; D005765:Gastrointestinal Agents; D010276:Parasympatholytics; D008139:Loperamide; D000068238:Lubiprostone; D000527:Alprostadil; D008550:Melatonin